Letter to the Editor

Prosthetic hip joint infection caused by Campylobacter fetus: A case report and literature review

Mª José Zamora-López
Patricia Álvarez-García
Marta García-Campello

Microbiología y Parasitología, Hospital de Pontevedra

Sir,

Campylobacter spp usually causes gastrointestinal illness and occasionally severe systemic infections. Most cases of intestinal campylobacteriosis are caused by Campylobacter jejuni or Campylobacter coli [1] but Campylobacter fetus is the most commonly detected pathogen causing Campylobacter bacteraemia [2,3]. Septic arthritis caused by this microorganism have been reported previously and are likely to become more common given the increased numbers of devices implanted and widespread use of immunosuppressive therapy.

These microorganisms are fastidious and require microaerobic growth conditions and appropriate culture methods. It is a microaerophile, Gram-negative, spiral-shaped bacterium that grows between 25°C and 37°C. The incubation temperature of 42°C, which is often routinely used to isolate Campylobacter spp, precludes the recovery of at least 20% of C. fetus isolates that do not grow at this temperature. On the other hand, use of cephalothin containing media, for the selective isolation of C. jejuni and C. coli, inhibits growth of C. fetus. It is also remarkable that microorganisms associated with prosthetic joint infections (PJI) are found in biofilms; thus, methods such as implant vortexing and sonication, which sample the prosthesis surface, provide improved sensitivity for PJI diagnosis compared to conventional periprosthetic tissue cultures [4].

Moreover, it is described the use of extraintestinal samples as blood or cerebrospinal fluid, which have less contaminating organisms and allow detection without the use of selective media [5]. Once a suspected C. fetus isolate is obtained, phenotypic or molecular methods can be used to confirm the species. In many cases, phenotypic methods have limitations and genotypic identification of the species has been recommended. Subspecies differentiation has no direct clinical relevance but might support a better understanding of the epidemiology.

Infections mainly affect persons at higher risk, including elderly and immunocompromised individuals [6]. Septicaemia, with fever but without apparent localized infection, is reported in most of cases [3,6]. Other manifestations may be the result of neurological infections, osteomyelitis, lung abscesses, arthritis, perinatal infections and vascular pathology [7,8,9]. Predisposing factors for C. fetus infection include conditions that result in immunosuppression, cardiovascular disease with valve abnormalities, liver disease, diabetes mellitus and medical device implants. Elderly people and pregnant women, without any underlying disease are also at risk [3,7]. In healthy young are rarely reported and such infections, are generally associated with occupational contact with animals [5]. In relation to the pathogenesis, the isolation or detection of DNA of C. fetus from stools of healthy people indicates that intestinal colonization may also occur without diarrhoea [10]. The limited ability of these microorganisms to breach the host defenses in otherwise healthy individuals may explain why dissemination of infections is mainly observed in immunocompromised individuals [6,11]. It has been demonstrated for this pathogen the preference for endovascular surfaces and a genomic variation that contributes to differences in the clinical infections and virulence [12].

We report a case of C. fetus infection involving a prosthetic hip joint. We considered immunocompromised patients to be those receiving chemotherapy, radiotherapy, or immunosuppressors. Blood cultures were processed using the BD BACTEC FX (Becton Dickinson, Sparks, MD) and microbiological cultures were realized by standard procedures. Identification and determination of antibiotic susceptibility were performed using Phoenix Automated Microbiology System (BD Diagnostic Systems) and Epsilon Test (BioMérieux, France). EUCAST breakpoints were applied (EUCAST 2014). We reviewed the literature regarding Campylobacter PJI.
The case was a 60-year-old male with severe pain in left hip joint. Nonspecific febrile was the main symptom. He had undergone a left total hip replacement 10 years earlier. Associated risk factors were: elderly, diabetes mellitus, immunosuppressive disease, vascular pathology and prosthetic hip joint. Clinical signs were lumbar and thoracic pain, anorexia, nausea, crampy lower abdominal pain, pleural effusion, chronic obstructive pulmonary disease and heart failure.

Biochemical and blood parameters were: haemoglobin concentration 9.7 g/dl (normal range: 13.5-17.5 g/dl), neutrophil count 13.1 x 10⁹/L (normal range: 1.8-8 x 10⁹/L), erythrocyte sedimentation rate 65 mm/h (normal range: 0-10 mm/h), C-reactive protein 14.45 mg/dl (positive > 1 mg/dl), glutamate pyruvate transaminase 64 U/L (normal range 7-40 U/L) and gamma-glutamyl-transpeptidase 265 U/L (normal range 10-50 U/L).

The fluid obtained from hip aspirate contained numerous white blood cells and was positive for C. fetus after 48 h of incubation. The same organism was grown from blood cultures and tissue taken from around the prosthesis. Interestingly, he did not have gastrointestinal or systemic symptoms and signs preceding or during the hip joint infection.

The infection required total removal of the prosthesis and the treatment in the first period of their income was imipenem associated with azithromycin for 6 weeks. In the second half, after 15 days without antibiotics new samples were microbiologically negatives. The absence of microorganisms was demonstrated and held on prosthetic replacement removing the spacer. The clinical course was favourable.

Twenty one cases (including one case) have been reported (table 1). Fourteen patients were infected with C. fetus, three with C. jejuni and one with C. coli, C. gracilis, C. lari or C. upsaliensis. The average age of C. fetus infection was 70.79 years (SD = 10.44). The antimicrobial therapy used was variable employing imipenem, gentamicin, amoxicillin, azithromycin, chloramphenicol, tetracycline, erythromycin, ceftriaxone or roxithromycin. The duration of treatment was very different, from 3 days to 3 months for patients with C. fetus infections.

C. fetus is a pathogen affecting almost exclusively patients with immunosuppression and chronic debilitating diseases. The patients with joint replacements are a target to consider too. Recent literature insured that yearly number of combined knee and hip arthroplasties are increasing [13]. The infection of prosthetic devices is rare but it is possible that other cases go unrecognized as Campylobacter spp may require prolonged incubation on media routinely used for suspected prosthetic joint infection.

This microorganism has a protein surface layer which provides resistance to opsonization, easily form an extraintestinal infectious focus [14] and can cause systemic infections and others (lung abscess, urinary infection, meningitis, subdural abscess, arthritis, peritonitis and cholecystitis). Furthermore, C. fetus shows a special tropism for the human vascular endothelium via bacteria surface receptors [15,16], be an added risk factor in these complicated patients [9].

We report here one case of infection caused by C. fetus in a patient with vascular pathology and prosthetic hip joint. In our study we highlight various aspects. On the one hand the diagnosis in our patients was made by blood cultures, fluid obtained from hip aspirate and tissue taken from around the prosthesis. Furthermore this case occurred without diarrhoea, as the least of the cases described in the series. Finally antimicrobial therapy was carried out by azithromycin and imipenem for 6 weeks and the infection required total removal of the prosthesis. The duration of treatment in cases of table 1 with C. fetus infection was very different, from 3 days with gentamicin and azithromycin to 3 months with ceftriaxone and roxithromycin.

Addition, we report here 20 Campylobacter PJIs by others authors where fourteen patients were infected with C. fetus (table 1) [17-28]. The predominance of C. fetus is in keeping with its propensity to cause bacteraemia, possibly related to its relative resistance to the bactericidal activity of serum [29]. The therapeutic regimens and the treatment duration were quite different. Most patients were elderly and immunocompromised, were elderly where its shows the difference in the mean age of infected patients, 28.6 years for C. jejuni /C. coli versus 68.4 years for C. fetus described previously by other authors [30].

All patients had risk factors such as chronic lymphocytic leukaemia, heart failure, diabetes mellitus, immunosuppressive therapy, liver cirrhosis, lung cancer, renal transplant and rheumatoid arthritis being susceptibility to infection by this organism and others.

Our patients demonstrates the typical features of patients with campylobacter joint prosthesis infection as most are elderly, immunocompromised and nonspecific febrile illness. In contrast to most cases reported, this case was diagnosed without diarrhoea in a patient with vascular pathology, in addition to being a carrier of a prosthetic hip joint.

The therapeutic regimens, duration and surgical strategies (one or two stage resection arthroplasties, implant retention or debridement) of these patients were quite different. The most cases of C. fetus and C. jejuni PJIs were treated with a combination of antimicrobials. Our patient was successfully treated consisting of removal of the prosthesis, surgical washout and debridement. The antimicrobial therapy was included carbapenems associated with macrolides in the first time. It is possible that the early removal and treatment contributed to the favourable outcome of case. It is not clear what the most effective antimicrobial therapy was or its duration, but from the cases reported long-term suppression appears unnecessary. The choice of antibiotics for treatment is controversial; some authors advocate the use of imipenem since C. fetus infections in immunocompromised patients are very serious. Ciprofloxacin and macrolides were an adequate choice for other cases described [31,32]. Antimicrobial regimens for the management of Campylobacter PJIs included β-lactams, aminoglycosides, macrolides, fluoroquinolones, clindamycin and tetracyclines in other cases.
C. fetus infection is rare, but can have important implications for patients with prosthetic joints. This infection should be suspected particularly in those patients with nonspecific febrile illness, acute gastroenteritis and immunosuppressive diseases, furthermore, this infection can be related to prosthetic devices in hospitalized patients being an important systemic disease. Most of cases occurring after recent gastroenteritis, consideration should be given to postponing elective arthro-

| Species | N° of cases | Age range | Male patients (%) | Prosthetic hip joint infection (N°) | Prosthetic knee joint infection (N°) | Underlying disease or relevant exposure |
|---------|-------------|-----------|-------------------|-----------------------------------|------------------------------------|----------------------------------------|
| C. fetus | 14 | 52-88 | 57 | 8 | 4 | Cattle Farmer |
| David et al | a | 72 | Male | - | Knee | Cattle Farmer |
| Yao et al | b | 75 | Male | Hip | - | Chronic Lymphocytic Leukemia, Prednisone |
| Bates et al | c | 68 | Female | Hip | - | Rheumatoid Arthritis, Prednisolone |
| Chambers et al | d | 72 | Male | Hip | - | Alcohol Abuse, Chronic Granulocytic Leukemia, Hypertension |
| Joly et al | e | 70 | Male | Hip | - | Liver Cirrhosis, Alcohol Abuse |
| Meyer et al | f | 71 | Female | - | Knee | Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, Rheumatoid Arthritis |
| g | 53 | Male | * | * | Diabetes Mellitus, Hypertensive Cardiomyopathy, Rheumatoid Arthritis |
| h | 80 | Female | ** | ** | Diabetes Mellitus, Hypertensive Cardiomyopathy, Rheumatoid Arthritis |
| Prendki et al | i | 88 | Male | Hip | - | Lung Cancer |
| j | 70 | Female | - | Knee | Liver Cirrhosis |
| k | 85 | Female | Hip | - | Liver Cirrhosis |
| l | 52 | Female | - | Knee | - |
| m | 75 | Male | Hip | - | Renal Transplant |
| Current | n | 60 | Male | Hip | - | Diabetes Mellitus, Immunosuppressive Disease, Vascular Pathology |
| C. jejuni | 3 | 60-77 | 100 | 1 | 2 | AIDS, B Cell Lymphoma, Haemophilia |
| Peterson et al | a | 60 | Male | Hip | - | Cattle Farmer |
| Shawn et al | b | 75 | Male | - | Knee | Cattle Farmer |
| Prendki et al | c | 77 | Male | - | Knee | Immunosuppressive Disease |
| C. coli | 1 | 60 | 100 | 1 | 0 | Obesity, Hypertension, Ingestion of contaminated raw oysters |
| Sharp et al | a | 60 | Male | Hip | - | Cattle Farmer |
| C. gracilis | 1 | 74 | 100 | 0 | 1 | Cattle Farmer |
| Almeida et al | a | 74 | Male | - | Knee | Cattle Farmer |
| C. larl | 1 | 81 | 100 | 1 | 0 | Tibial Osteoblastic Osteosarcoma |
| Werno et al | a | 81 | Male | Hip | - | Cattle Farmer |
| C. upsaliensis | 1 | 24 | 100 | 0 | 1 | Cattle Farmer |
| Issartel et al | a | 24 | Male | - | Knee | Cattle Farmer |

*Cellulitis of the right leg; **Septic arthritis of the right shoulder.
plasty surgery in patients who have had a recent episode of bacterial gastroenteritis.

*Campylobacter* infections of prosthetic devices are likely to become more common given the increased numbers of devices implanted and widespread use of immunosuppressive therapy.

Finally, based on our review of the literature, we concluded that it is important for clinicians should alert the clinical microbiology laboratory to the possibility of *C. fetus* infection when there is a compatible clinical syndrome, so that appropriate culture media and incubation conditions are used.

**FUNDING**

None to declare

**CONFLICTS OF INTEREST**

The authors declare that they have no conflicts of interest

**REFERENCES**

1. Gillespie IA, O’Brien SJ, Frost JA, Adak GK, Horby P, Swan AV, et al. A case-case comparison of *Campylobacter coli* and *Campylobacter jejuni* infection: a tool for generating hypotheses. Emerg Infect Dis 2002; 8:937-42. DOI: 10.3201/eid0809.010187

2. Fernandez-Cruz A, Munoz P, Mohedano R, Valero M, Marin M, Alcalá L, et al. *Campylobacter* bacteraemia: clinical characteristics, incidence, and outcome over 23 years. Medicine (Baltimore) 2010;89:319-30. DOI: 10.1097/MD.0b013e3181f2638d

3. Pacanowski J, Lalande V, Lacombe K, Boudraa C, Lesprit P, Legrand P, et al. *Campylobacter* bacteraemia: clinical features and factors associated with fatal outcome. Clin Infect Dis 2008;47:790-6. DOI: 10.1086/591530

4. Trampuz A, Piper KE, Jacobson MJ, Hanssen AD, Unni KK, Osmon DR, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med. 2007;357(7):654-63. DOI: 10.1056/NEJMoa061588

5. Wagenaar JA, van Bergen MA, Blaser MJ, Tauxe RV, Newell DG, van Putten JP. *Campylobacter* Fetus Infections in Humans: Exposure and Disease. Clin Infect Dis. 2014;58(11):1579-86. DOI: 10.1093/cid/ciu085

6. Gazeigne L, Legrand P, Renaud B, Bourra B, Taillandier E, Brun-Buisson C, et al. *Campylobacter Fetus* blood-stream infections: risk factors and clinical features. Eur J Clin Microbiol Infect Dis 2008;27:185-9. DOI: 10.1007/s10096-007-0415-0

7. Man SM. The clinical importance of emerging *Campylobacter* species. Nat Rev Gastroenterol Hepatol 2011;8:669-85. DOI: 10.1038/nrgastro.2011.191

8. Fujihara N, Takakura S, Saito T, Inuma S. A case of perinatal sepsis by *Campylobacter fetus* susp. Fetus infection successfully treated with carbapenem-case report and literature review. J Infect 2006;53:e199-202. DOI: 10.1016/j.jinf.2006.01.009

9. Hideharu H, Mitsuaki M, Hiroshi F, et al. Myotic Abdominal Aortic Aneurysm Caused by *Campylobacter fetus*: A Case Report and Literature Review. Ann Vasc Surg.2014;50(3):232-6. DOI: 10.1016/j.avsg.2014.05.021

10. Rennie RP, Strong D, Taylor DE, Salama SM, Davidson C, Tabor H. *Campylobacter fetus* diarrhea in a Hutterite colony: epidemiological observations and typing of the causative organism. J Clin Microbiol. 1994;32(3):721-4. DOI: 10.1128/JCM.7910829

11. Brah S, Chiche L, Brun M, Schleinitz N, Harle JR, Durand JM. *Campylobacter fetus* Bacteremia Revealed by Cellulitis without Gastrointestinal Symptoms in the Context of Acquired Hypogammaglobulinemia: A Report of Three Cases. Case Rep Gastrointest Med. 2011;2011:628902. DOI: 10.1155/2011/628902

12. Van der Graaff-van Bloois L, Miller WG, Yee E, Duim B, Wagenaar JA. Whole genome sequencing of *Campylobacter fetus* subspecies. In: American Society for Microbiology General Meeting, San Francisco, CA, 16-19 June 2012.

13. Vasoo S, Schwab JJ, Cunningham SA, Robinson TJ, Cass JR, Berbari EF, et al. *Campylobacter* prosthetic joint infection. J Clin Microbiol. 2014;52(5):1771-4. DOI: 10.1128/JCM.03572-13

14. Blaser MJ, Smith PF, Repine JE, Joiner KA. Pathogenesis of *Campylobacter fetus* infections. Failure of encapsulated *Campylobacter fetus* to bind C3b explains serum and phagocytosis resistance. J Clin Invest. 1988;81(5):1434-44. DOI: 10.1172/JCI13474

15. Morrison VA, Lloyd BK, Chia JK, Tuazon CU. Cardiovascular and bacteraemic manifestations of *Campylobacter fetus* infection: case report and review. Rev Infect Dis. 1990;12(3):387-92. DOI: 10.1128/JCM.03572-13

16. Melendez BA, Hollis HW Jr, Rehring TF. Myotic popliteal aneurysm rupture secondary to *Campylobacter fetus*. Ann Vasc Surg. 2015;29(1):122. e9-11. DOI: 10.1016/j.avsg.2014.05.021

17. Prendki V, Marmor S, Zeller V, Lhotellier L, Mégraud F, Desplaces N. *Campylobacter fetus* bacteremia: an evolving disease in France. J Clin Microbiol. 1994;32(3):721-4. DOI: 10.1128/JCM.03572-13

18. David J, Nasser RM, Goldberg JW, Reed KD, Earl MD. Bilateral prosthetic knee infection by *Campylobacter fetus*. J Arthroplasty. 2005;20(3):401-5. DOI: 10.1016/j.arth.2014.05.021

19. Yao JD, Ng HM, Campbell I. Prosthetic hip joint infection due to *Campylobacter fetus*. J Clin Microbiol. 1993;31(12):3323-4. DOI: 10.1128/JCM.7910829

20. Bates CJ, Clarke TC, Spencer RC. Prosthetic hip joint infection due to *Campylobacter fetus*. J Clin Microbiol. 1993;31(12):3323-4. DOI: 10.1128/JCM.7910829

21. Chambers ST, Morpeth SC, Laird HM. *Campylobacter fetus* prosthctic hip joint infection: successful management with device retention and review. J Infect. 2005;50(3):258-61. DOI: 10.1016/j.jinf.2004.03.017

22. Joly P, Boissonnas A, Fourrier R, Khalifa P, Vedel G, Cremer GA, et al. Septic arthritis caused by *Campylobacter fetus*. Rev Rhum Mal Osteoartic. 1986;53(4):223-6. DOI: 10.1128/JCM.7910829
Prosthetic hip joint infection caused by *Campylobacter fetus*: A case report and literature review

Mª J. Zamora-López, et al.

Rev Esp Quimioter 2018;31(1): 53-57

23. Meyer A, Theulin A, Chatelus E, Argemi X, Sordet C, Javier RM, et al. *Campylobacter fetus* infection in three rheumatoid arthritis patients treated with rituximab. Ann Rheum Dis. 2012;71(6):1094-5. DOI: 10.1136/annrheumdis-2011-200719

24. Peterson MC, Farr RW, Castiglia M. Prosthetic hip infection and bacteremia due to *Campylobacter jejuni* in a patient with AIDS. Clin Infect Dis. 1993;16(3):439-40. https://www.ncbi.nlm.nih.gov/pubmed/8452956

25. Sharp SE. *Campylobacter coli* prosthetic hip infection associated with ingestion of contaminated oysters. J Clin Microbiol. 2009;47(10):3370-1. DOI: 10.1128/JCM.00417-09

26. Almeida NJ, Murthy MH, Preheim LC. Prosthetic Knee joint infection caused by *Campylobacter gracilis*. Infect Dis Pract. 2009 17:118-119. https://journals.lww.com/infectdis/Abstract/2009/03000/Prosthetic_Knee_Joint_Infection_Caused_by.13.aspx

27. Werno AM, Klener JD, Shaw GM, Murdoch DR. Fatal case of *Campylobacter lari* prosthetic joint infection and bacteremia in an immunocompetent patient. J Clin Microbiol. 2002;40(3):1053-5. https://www.ncbi.nlm.nih.gov/pubmed/11880437

28. Issartel B1, Pariset C, Roure C, Boibieux A, Peyramond D. Successful treatment of prosthetic knee infection due to *Campylobacter upsaliensis*. Eur J Clin Microbiol Infect Dis. 2002;21(3):234-5. DOI: 10.1007/s10096-001-0693-x

29. Blaser MJ, Smith PF, Kohler PF. Susceptibility of Campylobacter isolates to the bactericidal activity of human serum. J Infect Dis. 1985;151(2):227-35. https://www.ncbi.nlm.nih.gov/pubmed/3968449

30. Bessède E, Lehours P, Labadi L, Bakiri S, Méraud F. Comparison of characteristics of patients infected by *Campylobacter jejuni*, *Campylobacter coli*, and *Campylobacter fetus*. J Clin Microbiol. 2014;52(1):328-30. DOI: 10.1128/JCM.03029-13

31. Martínez-Balzano C, Kohlitz PJ, Chaudhary P, Hegazy H. *Campylobacter fetus* bacteremia in a young healthy adult transmitted by khat chewing. J Infect. 2013;66(2):184-6. DOI: 10.1016/j.jinf.2011.11.020

32. Tremblay C, Gaudreau C, Lorange M. Epidemiology and antimicrobial susceptibilities of 111 *Campylobacter fetus* subsp. Fetus strains isolated in Quebec, Canada, from 1983 to 2000. J Clin Microbiol 2003;41:463-6. https://www.ncbi.nlm.nih.gov/pubmed/12517895